0001567619-22-000819.txt : 20220106
0001567619-22-000819.hdr.sgml : 20220106
20220106194853
ACCESSION NUMBER: 0001567619-22-000819
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220104
FILED AS OF DATE: 20220106
DATE AS OF CHANGE: 20220106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vexler Vladimir
CENTRAL INDEX KEY: 0001759506
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36721
FILM NUMBER: 22516206
MAIL ADDRESS:
STREET 1: 333 TWIN DOLPHIN DRIVE
STREET 2: SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Coherus BioSciences, Inc.
CENTRAL INDEX KEY: 0001512762
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273615821
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (650) 649-3530
MAIL ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: BioGenerics, Inc.
DATE OF NAME CHANGE: 20110210
4
1
doc1.xml
FORM 4
X0306
4
2022-01-04
0
0001512762
Coherus BioSciences, Inc.
CHRS
0001759506
Vexler Vladimir
COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY
CA
94065
0
1
0
0
Chief Scientific Officer
Common Stock
2022-01-04
4
A
0
40000
0.00
A
115154
D
Stock Option (Right to Buy)
15.94
2022-01-04
4
A
0
80000
0.00
A
2032-01-04
Common Stock
80000
80000
D
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Includes 112,083 RSUs.
Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan.
The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ McDavid Stilwell, as Attorney-in-Fact for Vladimir Vexler
2022-01-06